Spruce Biosciences Q2 2026 Results: Expenses Rise Ahead of the TA-ERT Filing

Spruce Biosciences (Nasdaq: SPRB) did not report revenue for the second quarter of 2026 and posted a net loss of $16.2 million, or $6.68 per basic and diluted share, versus a $2.1 million loss, or $3.50 per share, a year earlier. Operating expenses increased to $16.5 million as the company advanced TA-ERT and expanded pre-launch preparations. Cash and equivalents reached $96.3 million, while the planned TA-ERT regulatory filing and two clinical programs remain targeted for the fourth quarter of 2026.

Core financial results

The quarterly expense base increased substantially from the unusually low prior-year comparison. R&D expense was $12.2 million versus negative $0.4 million a year earlier, while G&A expense increased approximately 39% to $4.3 million.

Management’s explanations relate to the six-month expense comparison: higher R&D spending primarily reflected TA-ERT manufacturing scale-up and clinical development, partially offset by lower one-time product acquisition costs and the discontinued tildacerfont program. Higher G&A expense reflected personnel costs and professional fees supporting growth and pre-launch activities.

The net loss was slightly smaller than the operating loss because $0.8 million of interest and other income and a $0.6 million gain from changes in warrant and conversion-option liabilities more than offset $1.1 million of interest expense.

TA-ERT filing plans are driving the operational timeline

Spruce continues to target the fourth quarter of 2026 for its TA-ERT Biologics License Application for MPS IIIB. The company plans to seek accelerated approval using cerebrospinal fluid heparan sulfate non-reducing end, or CSF HS-NRE, as a surrogate endpoint considered reasonably likely to predict clinical benefit.

The FDA requested that Spruce initiate its TrAnsform confirmatory study while the BLA is under review as a condition of potential accelerated approval. The randomized study is expected to begin in the fourth quarter of 2026, enroll approximately 14 children between one and five years old with severe MPS IIIB, and assess TA-ERT’s effect on cognition.

A separate expanded-access program is also expected to begin in the fourth quarter. It is designed to enroll approximately 10 U.S. children who are not eligible for TrAnsform. Cure Sanfilippo Foundation and the National MPS Society made a combined $5.5 million strategic investment intended to partially fund this program.

Cash runway improved, but debt and the share count increased

Cash and equivalents nearly doubled between December 31, 2025 and June 30, 2026. Spruce believes the June quarter-end balance can fund planned operations and debt obligations into the second half of 2027, covering the planned BLA filing and initial confirmatory-study work under the current schedule.

The stronger cash position coincided with new debt and a larger outstanding share base. The release did not include a cash flow statement, so quarterly operating cash flow and free cash flow were not disclosed.

The company also increased prepaid expenses to $4.6 million from $0.4 million, consistent with a higher level of planned activity, although it did not provide a detailed breakdown of those prepayments.

Management’s perspective

CEO Javier Szwarcberg characterized the quarter as a period of execution ahead of the planned BLA submission. Management is simultaneously preparing the regulatory filing, confirmatory trial, expanded-access program and potential U.S. commercial launch, if TA-ERT receives FDA approval.

Spruce also added rare-disease and enzyme-replacement-therapy experience to its leadership team. Adrian Quartel became chief medical officer effective July 27, 2026, and Jessica Cohen Pfeffer became vice president of clinical development effective August 3, 2026.

Recent insider transactions

The supplied insider data showed no open-market insider purchases or sales during the latest six-month summary period and listed total insider holdings of approximately 96,960 shares. Stock awards are separate from open-market purchases.

Several other supplied entries did not identify a transaction type or amount and therefore do not support further interpretation.

Risks investors need to watch

• Regulatory acceptance remains uncertain. Spruce plans to seek accelerated approval based on a surrogate endpoint, but filing the BLA does not ensure that the FDA will accept or approve it.
• The confirmatory study is a required part of the accelerated-approval pathway. Delays in initiating or enrolling the approximately 14-patient TrAnsform trial could affect the regulatory timeline.
• Expenses have moved sharply higher. TA-ERT manufacturing, clinical development, staffing and pre-launch work increased the cost base before any potential product approval or commercial launch.
• The cash runway is finite. Management expects existing cash to fund operations and debt obligations into the second half of 2027, making the pace of clinical, regulatory and commercial spending an important variable.
• The capital structure has changed. Debt rose to $7.1 million and outstanding common shares approximately doubled from year-end, increasing both debt obligations and the share base.

Summary

Spruce Biosciences’ second-quarter loss widened as spending shifted toward TA-ERT manufacturing, clinical development and launch preparation. The larger cash balance provides funding into the second half of 2027 under management’s current plan, but the central near-term tests are execution of the fourth-quarter BLA submission, initiation of the required TrAnsform study and management of the higher expense base.